Roxatidine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Roxatidine acetate
Roxatidine acetate.svg
Systematic (IUPAC) name
2-oxo-2-(3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino)ethyl acetate
Clinical data
Oral
Pharmacokinetic data
Bioavailability 80–90%
Protein binding 5–7%
Metabolism Hepatic deacetylation
Minor involvement of CYP2D6 and CYP2A6
Half-life 5–7 hours
Excretion Renal
Identifiers
78628-28-1 N
A02BA06
PubChem CID 5105
DrugBank DB08806 YesY
ChemSpider 4926 YesY
UNII IV9VHT3YUM YesY
KEGG D08495 YesY
ChEMBL CHEMBL46102 YesY
Chemical data
Formula C19H28N2O4
348.437 g/mol
 N (what is this?)  (verify)

Roxatidine acetate is a specific and competitive histamine H2 receptor antagonist drug that is used to treat gastric ulcers, Zollinger–Ellison syndrome, erosive esophagitis, gastro-oesophageal reflux disease, and gastritis.[1][2]

Pharmacodynamic studies showed that 150 mg of roxatidine acetate were optimal in suppressing gastric acid secretion, and that a single bedtime dose of 150 mg was more effective than a dose of 75 mg twice daily in terms of inhibiting nocturnal acid secretion.[1]

It is available in countries including China, Japan, Korea, Germany, Italy, the Netherlands, Greece and South Africa.[2]

References[edit]